Neukio Biotherapeutics and Unitree Robotics have secured fresh funding.
Neukio Biotherapeutics nets $40m led by LAV
Neukio Biotherapeutics Co, Ltd, a biotech firm that specialises in the R&D of immune cell drugs, has raised $40 million in its angel round led by Lilly Asia Ventures (LAV).
IDG Capital alongside healthcare-led Chinese investment firm Sherpa Healthcare Partner also joined the round, per a company statement on Friday.
Neukio plans to invest its first external financing proceeds towards the developments of research infrastructure, immune cell technology platforms and drugs.
The firm, established in May by Dr Richard Wang who served as founding CEO of Fosun Pharma and Kite Pharma’s joint venue Fosun Kite, targets the oncology area with its generic allogenic cell therapies.
“Cell therapy will be an important weapon in the fight against cancers. With the deepening understanding of immuno-oncology, and advancement of gene editing technologies, different types of cell therapy will continue to expand the boundaries of cancer therapy,” said IDG Capital investment director Haoyue HU in the statement.
Shunwei backs Unitree Robotics
Shunwei Capital announced on Friday that it has led a $10-million Series A round funding in quadruped robots specialist Unitree Robotics.
The new development comes over a year in May last year after Unitree had raised an undisclosed sum in its pre-A++ round from Sequoia Capital China, Temasek-backed Vertex Ventures China, as well as technology and internet-driven Chuxin Capital.
Since its inception in 2016 in Hangzhou, Unitree has been active in the development and commercialisation of quadruped robots and components for consumers.
Go1, which is the latest proprietary robot product, is able to meet the scenarios such as running and strolling. Unitree said the functions are expanding to conversational AI, photography, among others.
Unitree’s early-stage investors also include Decent Capital, Var Capital, AIoT innovation and acceleration platform Arm Accelerator, Binhe Capital, among others.